Paper Details

  1. Home
  2. Paper Details

A novel substitution in NS5A enhances the resistance of hepatitis C virus genotype 3 to daclatasvir.

Author: BittarCintia, ChenShucheng, Fernandes CamposGuilherme Rodrigues, HarrisMark, MartinelliAna de Lourdes Candolo, PereiraLeonardo Régis Leira, RahalPaula, SouzaFernanda Fernandes, Vilela RodriguesJoão Paulo, WardJoseph

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

This study investigated the effect of a novel NS5A substitution (S98G) on replication fitness and resistance to DAAs in hepatitis C virus genotype 3. The S98G substitution, in combination with the previously characterized resistance-associated substitution (RAS), Y93H, resulted in a significant increase in daclatasvir resistance.
Paper Details　
Original Abstract of the Article :
Hepatitis C virus (HCV) genotype 3 presents a high level of both baseline and acquired resistance to direct-acting antivirals (DAAs), particularly those targeting the NS5A protein. To understand this resistance we studied a cohort of Brazilian patients treated with the NS5A DAA, daclatasvir and the ...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8116786/

データ提供：米国国立医学図書館（NLM）

Hepatitis C Virus Resistance: A Case of Evolution in Action

The [treatment of hepatitis C virus (HCV)] has been revolutionized by the advent of [direct-acting antivirals (DAAs)], but the virus has shown a remarkable ability to [evolve and develop resistance] to these medications. This study examines a [cohort of Brazilian patients] treated with [daclatasvir, an NS5A targeting DAA], highlighting a [novel substitution] in the [NS5A protein] that contributes to [resistance].

A Novel Substitution: A Case of Viral Adaptation

The researchers identified a [novel substitution] at [amino acid residue 98] in the [NS5A protein], specifically [serine to glycine (S98G)]. This mutation, combined with a [previously characterized resistance-associated substitution (RAS)] at [Y93H], significantly increased [resistance to daclatasvir]. It's like a desert plant adapting to a harsh environment, developing unique characteristics to survive.

Implications for HCV Treatment

This finding has important implications for [HCV treatment], underscoring the need for [continued vigilance] in monitoring for [resistance] and [developing new strategies] to combat [HCV evolution]. It's like constantly seeking new oases in the desert to ensure a successful journey.

Dr. Camel's Conclusion

This study serves as a reminder that [HCV] is a cunning and adaptable foe. While [DAAs] have revolutionized [HCV treatment], we must remain vigilant in our efforts to [understand and combat resistance]. Just as a desert traveler must constantly adjust their route to avoid treacherous terrain, we must continue to adapt our strategies to stay ahead of this evolving virus.

Date :
  1. Date Completed 2021-05-13
  2. Date Revised 2022-01-10
Further Info :

Pubmed ID

33141008

DOI: Digital Object Identifier

PMC8116786

Related Literature

Article Analysis
・Effects of daclatasvir
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.